Clinical and Medico-economic Evaluation of a Rapid Test (ePlex-BCID®, GenMark) for the Diagnosis of Bacteremia and Fungemia. (HEMOFAST)
Bacteremia Sepsis, Fungemia
About this trial
This is an interventional diagnostic trial for Bacteremia Sepsis focused on measuring multiplex PCR, blood culture, rapid diagnosis
Eligibility Criteria
Inclusion Criteria:
Patient with bacteremia and/or fungemia defined by :
1/ the presence of clinical signs of sepsis; AND 2/ a positive blood culture, i.e. the growth of at least one species of bacteria or micromyces in at least one blood culture vial
- Patient Hospitalized at Grenoble University Hospital (only North site) and seen by a physician from the antibiotic stewardship team
- First blood culture positive for the patient's sepsis episode
- Informed and written consent signed by the patient or his legal representative or the doctor in case of emergency.
Exclusion Criteria:
- Patients mentioned in the law articles L1121-5 to L1121-8 from French Health Code
- Patients hospitalized in palliative care unit
- Persons with an estimated survival of less than one month
Sites / Locations
- Grenoble University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Multiplex PCR + Current strategy
Current strategy alone
Results of the multiplex PCR will be send as soon as possible to the infectious disease phycian for quick adaptation of antibiotic treatment. Positive blood cultures will also undergo current diagnosis strategy for bacteremia and fungemia.
Current diagnostic strategy based on the identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram